Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

Leukemia

Volumn 21, Issue 8, 2007, Pages 1700-1707

  van Rhenen, A ^a   Moshaver, B ^a   Kelder, A ^a   Feller, N ^a   Nieuwint, A W M ^a   Zweegman, S ^a   Ossenkoppele, G J ^a   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD123 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD22 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CELL MARKER; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; LECTIN 1; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL COMPARTMENTALIZATION; CELL LINEAGE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; STEADY STATE;

EID: 34447646569     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404754     Document Type: Article

References (20)

1. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380-1390.
2. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
3. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.
4. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multi-parameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-3085.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
6. Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA et al. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-MO): Reduced immunogenicity and high frequency of CD34+/ CD38- leukemic progenitors. Leukemia 1999; 13: 1513-1518.
7. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11: 6520-6527.
8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261.
9. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-1784.
10. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
11. Bakker AB, Van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA et al. C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64: 8443-8450.
12. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886.
13. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003; 88: 983-993.
14. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035.
15. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
16. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
17. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2: 229-240.
18. van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der MM, Weijers GW et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 2003; 88: 134-147.
19. van Stijn A, Kok A, van Stalborch MA, van der Pol MA, Feller N, Westra AH et al. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia 2004; 18: 875-877.
20. Hess CJ, Denkers F, Ossenkoppele GJ, Waisfisz Q, McElgunn CJ, Eldering E et al. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia 2004; 18: 1981-1988.